RxDoctor Payments Data

Douglas Severance, MD

Family Medicine · San Ramon, CANPI 1639289838

Payments from drug & device makers

$15,348in general payments, 2019–2025

Across 871 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$2K
  • Pfizer$1K
  • Boehringer Ingelheim$956
  • AstraZeneca$909
  • Lilly USA, LLC$882
  • plus $6K from 51 others

What the payments were for

  • Food & beverage$15,304100%
  • Education$440%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,348 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$292,791
Medicare patients
536
Services billed
3,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide193$251,767
MounjaroTirzepatide78$115,299
JardianceEmpagliflozin115$112,699
EliquisApixaban77$80,039
NuplazidPimavanserin Tartrate12$57,313
TrulicityDulaglutide22$34,606
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog50$32,144
MyrbetriqMirabegron26$27,186
XareltoRivaroxaban24$26,741
Repatha SureclickEvolocumab22$23,218
FarxigaDapagliflozin Propanediol16$19,518
CreonLipase/Protease/Amylase11$19,103
JanuviaSitagliptin Phosphate14$18,761
GemtesaVibegron22$17,595
Tresiba Flextouch U-200Insulin Degludec17$10,649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$3,075$251,767193 claims
Lilly USA, LLCMounjaro, Trulicity$882$149,905100 claims
Boehringer IngelheimJardiance$956$112,699115 claims
PfizerEliquis, Paxlovid$1,311$84,327108 claims
Astellas Pharma US IncMyrbetriq$166$27,18626 claims
Johnson & JohnsonXarelto$121$26,74124 claims
AstraZenecaFarxiga, Symbicort$909$23,15730 claims
AbbVieCreon$2,079$19,10311 claims
MerckJanuvia$134$18,76114 claims
Sumitomo Pharma America, Inc.Gemtesa$122$17,59522 claims
Indivior Inc.Suboxone$454$9,64215 claims
BayerKerendia$529$8,01812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in San Ramon

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →